|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
22.92 USD |
+0.61% | +3.52% | -13.61% | |
April 26, 2025 at 02:03 pm EDT
This article is reserved for members Unlock the article: REGISTER NOW!
© Reuters – 2025
|
Pfizer’S Sasanlimab Combination Significantly Improves Event-Free Survival In Bcg-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer |
Apr. 26 |
RE |
|
US FDA asks Novavax to complete new clinical trial for delayed COVID-19 shot, WSJ reports |
Apr. 25 |
RE |
|
Report Says 25% Pharma Tariff Would Raise US Drug Costs by $51 Billion Annually |
Apr. 25 |
MT |
|
Report Says 25% Pharma Tariff Would Raise US Drug Prices by $51 Billion Annually, Reuters Reports |
Apr. 25 |
MT |
|
US pharma tariffs would raise US drug costs by $51 billion annually, report finds |
Apr. 25 |
RE |
|
Health Rounds: Exposure to bacterial toxin may explain earlier age colon cancer rise |
Apr. 25 |
RE |
|
Sector Update: Health Care Stocks Rise Late Afternoon |
Apr. 24 |
MT |
|
Sector Update: Health Care Stocks Advance Thursday Afternoon |
Apr. 24 |
MT |
|
Bristol Myers posts higher-than-expected quarterly revenue on cancer drug sales |
Apr. 24 |
RE |
|
Guardant Health, Pfizer Begin Partnership to Test Prospective Cancer Therapies in China |
Apr. 24 |
MT |
|
Guardant Health Announces Strategic Collaboration With Pfizer To Support Development And Commercialization Of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform |
Apr. 24 |
RE |
|
Guardant Health, Inc. Announces Strategic Collaboration with Pfizer, Inc. to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform |
Apr. 24 |
CI |
|
Vaccine-wary Slovak PM pauses COVID-19 shot purchases pending review |
Apr. 23 |
RE |
|
Arvinas Announces Results from the Veritac-2 Trial Selected as Late-Breaking Oral Presentation At the 2025 American Society of Clinical Oncology Annual Meeting |
Apr. 23 |
CI |
|
Novavax shares soar after FDA request raises hope for COVID vaccine approval |
Apr. 23 |
RE |
|
How companies are responding to Trump’s tariffs |
Apr. 22 |
RE |
|
How companies are responding to Trump’s tariffs |
Apr. 22 |
RE |
|
Trump Administration Mulls Cutting US Drug Prices to International Levels |
Apr. 22 |
MT |
|
Trump Mulls Cutting US Drug Prices to International Levels, Reuters Reports |
Apr. 22 |
MT |
|
Trump looking at cutting US drug prices to international levels, sources say |
Apr. 22 |
RE |
|
UK Medicines Regulator Approves Pfizer’s Hympavzi for Hemophilia A, B |
Apr. 22 |
MT |
|
UK’s MHRA Says Marstacimab Approved For Patients Aged 12 Years & Above With Haemophilia A Or B |
Apr. 22 |
RE |
|
TD Cowen Adjusts Price Target on Pfizer to $28 From $32, Maintains Hold Rating |
Apr. 22 |
MT |
|
Wolfe Research Adjusts Pfizer Price Target to $22 From $25, Keeps Underperform Rating |
Apr. 21 |
MT |
|
BofA Securities Adjusts Price Target on Pfizer to $26 From $29, Maintains Neutral Rating |
Apr. 21 |
MT |
PFE: Dynamic Chart
Pfizer, Inc. is the world’s leading pharmaceutical group. Net sales break down by family of products as follows:
– primary care products (47.4%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.;
– specialty care products (26.2%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.;
– oncology products (24.5%);
– other (1.9%).
The United States accounts for 60.8% of net sales.
More about the company
Buy
Average target price
29.50USD
Spread / Average Target
+28.69%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
